Greater Drop in Hemoglobin A1c With Empagliflozin + Metformin

Share this content:
Greater Drop in Hemoglobin A1c With Empagliflozin + Metformin
Greater Drop in Hemoglobin A1c With Empagliflozin + Metformin

FRIDAY, Aug. 12, 2016 (HealthDay News) -- Twenty-four weeks of empagliflozin + metformin correlates with a significantly greater reduction in hemoglobin A1c (HbA1c) compared with once-daily empagliflozin or twice-daily metformin, according to a study published online Aug. 4 in Diabetes Care.

Samy Hadjadj, M.D., Ph.D., from the Centre Hospitalier Universitaire Poitiers in France, and colleagues randomized 1,364 drug-naive patients with type 2 diabetes to empagliflozin + metformin, empagliflozin, or metformin for 24 weeks. The authors examined the change from baseline in HbA1c at week 24.

At week 24, the researchers observed reductions in HbA1c of −1.9 to −2.1 percent with empagliflozin + metformin twice-daily regimens; −1.4 percent with empagliflozin once-daily regimens; and −1.2 to −1.8 percent with metformin twice-daily regimens. Empagliflozin + metformin twice-daily regimens correlated with significantly greater reductions in HbA1c than for empagliflozin once-daily regimens (P < 0.001) and metformin twice-daily regimens (P < 0.01). Compared with metformin twice-daily regimens, empagliflozin + metformin twice-daily regimens correlated with significantly greater weight loss at week 24 (all P < 0.001). Across the groups, adverse event rates were similar.

"Initial combinations of empagliflozin + metformin for 24 weeks significantly reduced HbA1c versus empagliflozin once daily and metformin twice daily, without increased hypoglycemia, reduced weight versus metformin twice daily, and were well tolerated," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Boehringer Ingelheim and Eli Lilly, which manufacture empagliflozin and funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Montelukast Associated With Nightmares, Depression

Montelukast Associated With Nightmares, Depression

Odds of depression, aggressive behavior, suicide ideation, nightmares, headaches all increased

Alcohol Aids Cerebellar Deficit From Movement Disorder

Alcohol Aids Cerebellar Deficit From Movement Disorder

Cerebellar networks may play key role in symptom generation in these patients

Oral Beats Topical Isotretinoin for Treatment of Warts

Oral Beats Topical Isotretinoin for Treatment of Warts

Oral treatment shows better, earlier response than topical isotretinoin

is free, fast, and customized just for you!

Already a member?

Sign In Now »